Gabaergic Neurons In Neurodegeneration plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000617 | GABAergic neuron |
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:0000617 | GABAergic neuron | Exact |
| Cell Ontology | CL:4300028 | cerebellar GABAergic neuron (Mmus) | Exact |
GABAergic neurons are inhibitory neurons that utilize gamma-aminobutyric acid (GABA) as their primary neurotransmitter. They play crucial roles in maintaining neural circuit balance, preventing hyperexcitability, and coordinating information processing throughout the brain. Dysfunction of GABAergic neurons contributes significantly to hyperexcitability, seizures, and network dysfunction observed in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis[1].
GABAergic interneurons in the cortex and hippocampus are remarkably diverse[2]:
| Type | Target | Marker | Function |
|---|---|---|---|
| PV basket cells | Pyramidal soma | Parvalbumin | Fast, powerful inhibition |
| CCK basket cells | Pyramidal soma | CCK, CB1 | Modulated inhibition |
| Axo-axonic cells | Axon initial segment | Parvalbumin | Output control |
| Type | Target | Marker | Function |
|---|---|---|---|
| SST interneurons | Dendrites | Somatostatin | Dendritic inhibition |
| VIP interneurons | Dendrites | VIP | Disinhibition |
| Neurogliaform cells | Distal dendrites | NPY | Volume transmission |
GABAergic neurotransmission depends on specific machinery[3]:
Ligand-gated chloride channels with multiple subunits:
| Subunit | Location | Function |
|---|---|---|
| α1 | Widely distributed | Sedation |
| α2 | Anxiety, motor | Anxiolysis |
| α3 | Sparse | Muscle tone |
| α5 | Hippocampus | Memory |
Metabotropic receptors:
GABAergic dysfunction in AD is extensive[4]:
Amyloid-beta effects:
Tau pathology:
Network dysfunction:
| Approach | Target | Status |
|---|---|---|
| GABA-A modulators | Cl- channel | Approved |
| GABA-B agonists | GPCR | Research |
| Neurosteroids | Allosteric sites | Clinical trials |
GABAergic changes in PD are central to motor dysfunction[5]:
GABAergic loss is early and progressive[6]:
Cortical hyperexcitability features prominently[7]:
| Drug Class | Example | Mechanism | Indication |
|---|---|---|---|
| Benzodiazepines | Diazepam | Positive allosteric modulators | Anxiety, sedation |
| Barbiturates | Phenobarbital | Direct activation | Seizures |
| Neurosteroids | Allopregnanolone | δ subunit modulation | Depression |
The loss of GABAergic inhibition leads to network hyperexcitability through several interconnected mechanisms[1:1][8]:
GABAergic interneurons are critical for generating brain oscillations:
| Oscillation Type | Frequency | Interneuron Type | Function |
|---|---|---|---|
| Gamma | 30-100 Hz | PV basket cells | Cognition, attention |
| Beta | 13-30 Hz | SST, PV | Motor coordination |
| Theta | 4-8 Hz | HIPP interneurons | Memory, navigation |
| Ripple | 150-200 Hz | PV basket cells | Memory consolidation |
The disruption of these oscillations contributes to cognitive decline in neurodegenerative diseases[@klausberger2003][9].
PV-expressing interneurons are particularly vulnerable in several conditions[10][11]:
SST neurons show early dysfunction in AD:
GABAergic neurons exhibit specific vulnerabilities[12][13]:
Specific receptor changes in GABAergic neurons[14][15]:
| Receptor | Change | Consequence |
|---|---|---|
| GABA-A α1 | Downregulated | Reduced fast inhibition |
| GABA-A α5 | Altered | Memory deficits |
| GABA-B | Reduced | Plasticity impairment |
| KCC2 | Downregulated | Depolarizing GABA effects |
GABAergic changes in PD are central to motor dysfunction[16][17]:
Treatment Implications:
GABAergic loss is early and progressive[18][19]:
| Target | Approach | Status |
|---|---|---|
| GABA-A α1 | Positive allosteric modulators | Approved for anxiety |
| GABA-A α5 | Selective modulators | Clinical trials |
| GABA-B | Baclofen derivatives | Research |
| KCC2 | Enhancers | Preclinical |
ALS features prominent cortical hyperexcitability[7:1][20]:
Palop JJ, Mucke L. Epilepsy and hyperexcitability in Alzheimer's disease. Nat Rev Neurosci. 2010
Freund TF, Katona I. Perisomatic inhibition in neuronal networks. Neuron. 2007
Zhou X et al. GABAergic dysfunction in Alzheimer's disease. J Alzheimers Dis. 2022
Turner MR et al. Cortical hyperexcitability in amyotrophic lateral sclerosis. Lancet Neurol. 2018
Li M et al. GABAergic system breakdown in Alzheimer's disease. Ageing Res Rev. 2021
Pal A et al. GABAergic signaling in Parkinson's disease. Neuropharmacology. 2019
Menichetti L et al. Targeting GABAergic dysfunction in ALS. J Neurol. 2019
Fischer K et al. Early GABAergic deficits in ALS. Ann Neurol. 2020
Palop JJ, Mucke L. Epilepsy and hyperexcitability in Alzheimer's disease. Nature Reviews Neuroscience. 2010. ↩︎ ↩︎
Freund TF, Katona I. Perisomatic inhibition in neuronal networks. Neuron. 2007. ↩︎
Benarroch EE. GABA receptor heterogeneity, function, and implications for CNS disorders. Neurology. 2007. ↩︎
Zhou X, Chen Y, Mok K, et al. GABAergic dysfunction in Alzheimer's disease: from molecules to circuits. Journal of Alzheimer's Disease. 2022. ↩︎
Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends in Neurosciences. 2002. ↩︎
Albin RL, Mathiesen K, Watson M, et al. Preclinical evidence for early GABAergic dysfunction in Huntington's disease. Brain. 2020. ↩︎
Turner MR, Kiernan MC, Leigh PN, et al. Cortical hyperexcitability in amyotrophic lateral sclerosis. Lancet Neurology. 2018. ↩︎ ↩︎
Li M, Chen X, Ye Q, et al. GABAergic system breakdown in Alzheimer's disease: implications for pathogenesis. Ageing Research Reviews. 2021. ↩︎
Hu H, Gan J, Jonas P. Fast-spiking, parvalbumin+ GABAergic interneurons: from cellular diversity to function. Science. 2014. ↩︎
Kelley KW, Ben H, Park JS, et al. Parvalbumin interneurons mediate hippocampal GABAergic dysfunction in temporal lobe epilepsy. Brain. 2018. ↩︎
Murray AJ, Schnepf D, Riedemann T, et al. Parvalbumin-expressing interneurons: localization, function, and seizure onset in epilepsy. Neuroscientist. 2018. ↩︎
Marin O. Interneuron dysfunction in psychiatric disorders. Nature Reviews Neuroscience. 2012. ↩︎
Goncalves J, Baptista M, O'Brien A, et al. GABAergic defects in neurodegenerative diseases: connecting the dots. Trends in Pharmacological Sciences. 2019. ↩︎
Whitt JL, Masri R, Pulimood NS, et al. Pathogenic tau impairs fast-spiking neuron function in a mouse model of tauopathy. Brain. 2018. ↩︎
Devore S, Lee J, Bae J, et al. Network dysfunction in Alzheimer's disease: GABAergic contributions. Current Alzheimer Research. 2020. ↩︎
Pal A, Sharma RP, Bhattacharya P, et al. GABAergic signaling in Parkinson's disease: mechanisms and therapeutic potential. Neuropharmacology. 2019. ↩︎
Espay AJ, Fung W, Giuffrida JP, et al. Levodopa-induced dyskinesia in Parkinson disease: from clinic to cellular mechanisms. Movement Disorders. 2014. ↩︎
Burkhardt JM, Zironi S, Hajjar N, et al. GABAergic inhibition in Huntington's disease mouse model. Neurobiology of Disease. 2008. ↩︎
Gruber R, Koch R, Huber J, et al. Dystonia in Huntington's disease: GABAergic dysfunction. Brain. 2019. ↩︎
Fischer K, Braun A, Schmidt T, et al. Early GABAergic deficits in ALS: from molecules to behavior. Annals of Neurology. 2020. ↩︎
Menichetti L, Ciampi M, Pellegrini S, et al. Targeting GABAergic dysfunction in ALS: a new therapeutic strategy. Journal of Neurology. 2019. ↩︎